(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 34.2MM | +9% |
Gross Profit | 24.3MM | - |
Cost Of Revenue | 9.9MM | -46% |
Operating Income | -10.2MM | -59% |
Operating Expenses | 34.6MM | - |
Net Income | -10.7MM | -57% |
R&D | 10.9MM | -19% |
G&A | 11.3MM | -3% |
Marketing | 12.3MM | -5% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard, Chief Executive Officer of Heron, will participate in a fireside chat on Wednesday, April 10, 2024, at 11:00 AM ET at the 23rd Annual Needham Virtual Healthcare Conference. The conference is being held in a virtual format, April 8-11, 2024.
Heron Therapeutics ( NASDAQ:HRTX ) Full Year 2023 Results Key Financial Results Revenue: US$127.0m (up 18% from FY...
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2023 Earnings Call Transcript March 12, 2024 Heron Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by, and welcome to the Heron Therapeutics Fourth Quarter 2023 Conference Call. I […]
Q4 2023 Heron Therapeutics Inc Earnings Call
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Record Quarterly Sales for ZYNRELEF and Strong Oncology Franchise Performance
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 31, 2023 and highlighted recent corporate updates.
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of -0.65% and 74.71%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Evaluate the expected performance of Heron Therapeutics (HRTX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics are part of the Zacks Industry Outlook article.